EMA’s veterinary medicinal products committee recommends marketing authorization to Elanco’s Zenrelia to treat atopic dermatitis in dogs: Greenfield, Indiana Monday, June 16, ...

Arcutis Biotherapeutics, Inc. (NASDAQ:ARQT) is one of the 10 Best Small-Cap Growth Stocks to Buy According to Analysts. On ...

On June 9, Regeneron Pharmaceuticals and Sanofi (NASDAQ:SNY) announced promising interim results from the open-label Phase 4 ...

Outcomes were evaluated among children born between April 1980 and June 2019 by using data from 12 observational birth ...

Ilunocitinib tablets are currently available in Brazil, Canada and Japan, in addition to the US. Elanco noted that, once the ...

AbCellera Biologics' drug candidates in Phase 1 trials show promise, but financial losses and slow progress raise concerns.

A Google search on “diet and eczema” may be more misleading than helpful, warns pediatric dermatologist Sandipan Dhar.

Merck’s Animal Health division just fetched a major win as the EU's veterinary committee gave a tail-wagging thumbs-up to ...

ShareA new study led by researchers in the United Kingdom (UK) indicates that certain environmental exposures may affect a child’s risk of developing atopic eczema, a condition characterised by dry, ...

The positive opinion for Zenrelia, or ilunocitinib, opens the way for the product's marketing authorization in the European Union in the next 60 days. The company said it expects to launch Zenrelia ...

If there is any truth to the nursery rhyme “April showers bring May flowers,” you can get ready for allergy season and eczema flareups when the weather gets warmer. Depending on where you live, ...

US-based biotechnology company Arcutis Biotherapeutics has enrolled the first child in an open-label Phase II trial of Zoryve ...